Kornimate/medical-research-clean huggingface dataset:
identifying effective treatment for veterans unwilling to quit smoking

Conditions: Tobacco Dependence; Veterans

Summary: this project will generate knowledge about the effectiveness of enhanced chronic care, an intervention designed to enhance treatment use and smoking abstinence in veterans who are initially unwilling to quit. enhanced chronic care provides ongoing motivational interventions and interpersonal support designed to promote readiness to quit smoking. enhanced chronic care will be compared with standard care (brief advice to quit once per year) on criteria that are of great clinical and public health importance: use of cessation treatment and smoking abstinence. it is expected that enhanced chronic care will increase treatment use and smoking abstinence relative to standard care.

this project will generate knowledge about the effectiveness of enhanced chronic care, an intervention designed to enhance treatment use and smoking abstinence in veterans who are initially unwilling to quit. enhanced chronic care provides ongoing motivational interventions and interpersonal support designed to promote readiness to quit smoking. enhanced chronic care will be compared with standard care (brief advice to quit once per year) on criteria that are of great clinical and public health importance: smoking treatment reach (use of cessation treatment) and abstinence. it is expected that enhanced chronic care will increase treatment use and smoking abstinence relative to standard care. the investigators will evaluate these interventions using a 2-arm randomized controlled trial. veterans who smoke daily, but who are not willing to enter smoking cessation treatment, will be eligible to participate, with no obligation to quit smoking. participants (n=500) will be randomized to one of the following treatments: 1) enhanced chronic care (n=250) or 2) standard care (n=250). these intervention conditions will last 2 years to permit analysis of their cumulative impact on abstinence and treatment use

Eligibility criteria:
inclusion criteria: * not willing to set a quit date in the next 30 days * report smoking an average of 4 or more cigarettes daily for at least six months * read, write, and speak english * be medically eligible to use nicotine replacement therapy * if female, use an approved method of birth control if they use nicotine replacement therapy * agree to participate in the study * be at least 18 years old * be a veteran exclusion criteria: * unable to give informed, voluntary consent to participate * current use of any pharmacotherapy for smoking cessation not provided by the researchers during tobacco treatment * use of non-cigarette tobacco products as a primary form of tobacco use * incarceration

Keywords: tobacco dependence clinical trial veterans
glioma microenvironment an exploratory study

Conditions: Glioma of Brain

Summary: diffuse glioms are primary brain tumors characterized by infiltrative growth and high heterogeneity, which render the disease mostly incurable. advances in genetic analysis revealed that molecular and epigenetic alterations predict patients´s overall survival and clinical outcome. however, glioma tumorigenicity is not exclusively caused by its genetic alterations. the crosstalk between tumor cells and the surrounding microenvironment plays a crucial role in modulating glioma growth and aggressiveness. in this sense, to understand the tumor microenvironment would elucidate potential treatment alternatives. the focus will be to evaluate myeloid cells and cytokines levels.

the proposal is to study gene expression and early epigenetic changes in myeloid cells from brain tumors and co-culture experiments. tough rna-seq, atac-seg and subsequent analysis to monitor the differential gene expression through different time points followed by stimuli. the study will compare the obtained results with sequencing data from microglia of full-fledged human tumor samples (glioblastoma and low grade gliomas). additionally it will evaluated the immunologic characteristic of the tumor through cytokines levels analysis (tnf-α, il-4, il-6, il-8, il-10, il-13, ifn-γ, tgf-β e il-1ra).

Eligibility criteria:
inclusion criteria: * 18 - 65 years old with brain tumor * patients that will be submitted to brain tumor ressection exclusion criteria: * chronic neurodegenerative and inflamatory diseases

Keywords: glioma glioblastoma low grade tumor
effect of glucose-insulin-potassium on hyperlactatemia in patients undergoing valvular heart surgery

Conditions: Valvular Heart Disease

Summary: hyperlactatemia, occuring 10-20% in patients undergoing valvular heart surgery, is known to be associated with hemodynamic instability, organ dysfunction and increased postoperative morbidity and mortality. glucose-insulin-potassium(gik) has been constantly used as an adjuvant therapy in patients with myocardial infarction or in the patients undergoing valvular heart surgery to reduce the low cardiac output syndrome and mortality. gik is known to prevent excretion of lactate and to increase the extraction of lactate after reperfusion with various mechanism. in addition, it is also known to decrease ischemic-reperfusion injury of myocardium after cpb, to improve myocardial contractility, insulin resistance and hyperglucemia. as a result, it brings hemodynamic stability and sufficient oxygen supply to the tissue, which might reduce the incidence of hyperlactatemia after valvular heart surgery.


Eligibility criteria:
inclusion criteria: * patients(20 yr or older) undergoing elective valvular heart surgery under cardiopulmonary bypass(cpb) with more than 2 of following features: 1. congestive heart failure 2. infective endocarditis 3. redo valvular surgery 4. surgery combined with coronary bypass graft 5. multiple valvular surgery 6. expected cpb duration longer than 2 hr 7\> preoperative serum creatinine over 1.4 mg/dl 8\> preoperative hemoglobin level less than 12 mg/dl 9\> left ventricular ejection fraction less than 40% exclusion criteria: 1. emergency surgery 2. hemodynamic instability before surgery (mean arterial pressure \ 100 /min 3. need for pharmacological or mechanical assist for hemodynamic stability before surgery 4. baseline blood lactate level more than 2 mmol/l 5. on steroid or nsaid 6. hepatic dysfunction

Keywords: gik, valvular heart surgery, lactate
adaptation and pilot testing of a mindfulness-based insomnia and symptom management intervention for women with breast cancer receiving treatment in rural medically underserved areas

Conditions: Breast Cancer

Summary: women with breast cancer often experience multiple difficult symptoms, for example insomnia, fatigue, stress, and pain. this study is being done to test a mindfulness-based insomnia and symptom management intervention for women with breast cancer (nite2day). participants will complete six, 45-60 minute intervention sessions with a study therapist. intervention sessions will be conducted remotely via conference (i.e., zoom) or telephone. during these sessions, participants will learn mindfulness and cognitive-behavioral strategies to cope with nighttime sleep disturbances and daytime symptoms of fatigue, stress, and pain. participants will be asked to complete three, brief (15-20 minute) surveys that will ask questions about their background, cancer diagnosis and treatments, cancer symptoms, and experience with the intervention. participants will be compensated for completing all intervention sessions and surveys. total study duration is about 12 weeks. the greatest risk of this study is loss of confidentiality. benefits from participating might include learning skills to reduce nighttime sleep disturbances and daytime symptoms of fatigue, stress, and pain. information learned from this study may also benefit other patients with cancer in the future.


Eligibility criteria:
inclusion criteria: 1. stage 0-iv breast cancer diagnosis within past 12 months 2. self-report \>8 on the insomnia severity index, indicating at least mild symptoms of clinical insomnia 3. \>18 years old 4. life expectancy of \>12 months per medical chart or oncologist 5. ability to speak and read english, and intact hearing and vision exclusion criteria: 1. reported or suspected cognitive impairment confirmed via folstein mini-mental status exam \<25; 2. serious psychiatric (e.g., schizophrenia, suicidal intent) or medical condition (e.g., seizure disorder, narcolepsy, severe or moderate untreated sleep apnea) indicated by self-report, medical chart, or oncologist/provider that would contraindicate safe participation; 3. engagement in behavioral insomnia (e.g., cognitive-behavioral therapy for insomnia) or symptom management (e.g., pain coping skills training) interventions within past 6 months
small fiber assessment by cutaneous silent period

Conditions: Small Fiber Neuropathy

Summary: our primary objective in this study is to investigate the cutaneous silent period (csp) in normal subjects in the egyptian population, as it was not carried out before in egypt. the aim was to carry out the test in our unit to study the appropriate method, technique, and parameters of this new test so that we can apply it in future research. in addition, to obtain preliminary normative data of the test; onset latency, end latency, duration, and latency difference (ld) of csp, as well as assess the effect of age, height, upper limb length, and gender on csp values.

nerve conduction studies performed routinely in electromyoneurography laboratories deal mainly with large myelinated fast conducting nerve fibers. a reliable method allowing the study of small peripheral nerve fibers (aδ \& c) would be of interest (jovita et al., 2006). as they are initially affected and maybe the earliest exhibited sign of neuropathy. in recent years, the cutaneous silent period (csp) has received increased attention in health and disease. the csp is an inhibitory spinal reflex that appears following strong electrical stimulation of the cutaneous nerve and causes suppression of voluntary muscular contraction for a certain period of time (kofler et al., 2019). this action presents a reciprocal action to the nociceptive flexor withdrawal response (fwr) which serves as an 'excitatory reflex' increasing activity in primary flexor muscles. when taken into context, the interplay between the csp and fwr can clearly be seen. the evaluation of the csp represents a useful electrophysiological method for investigating the function of small fibers by using standard electromyography equipment (eckert et al., 2018).

Eligibility criteria:
inclusion criteria: * healthy participants able to cooperate and to follow instructions. * participants having a normal value for electrophysiological parameters (nerve conduction studies) * participants must be free from any musculoskeletal impairment of the limbs exclusion criteria: * participants with neurological disorders * participants with cognitive impairment * participants receiving medications that may affect the ncs * participants with small fiber neuropathy (burning sensation, pricking sensation, allodynia, and hyperalgesia) * participants with an abnormal value for nerve conduction studies * participants with musculoskeletal impairment of the limbs
cardiovascular risk markers in veterans with post traumatic stress disorder

Conditions: Cardiovascular Disease; Post Traumatic Stress Disorder

Summary: this is an observational study designed to determine whether veterans with ptsd have a higher risk of heart disease than those without ptsd. cardiovascular risk will be assessed by interview and review of medical records, carotid artery ultrasound, and blood tests measuring markers of inflammation. study participation is approximately 6 months. the eligible study population is veterans of operation iraqi freedom (oif) and operation enduring freedom (oef), age 28 through 38 years.


Eligibility criteria:
inclusion criteria: * oef/oif veterans at the vasdhs * between 28 and 38 years of age * willing to complete structured diagnostic interview for ptsd, cimt ultrasound and blood test * willing to have a review of their medical records * able to give informed consent * have a negative urine pregnancy test, if a woman of child-bearing age exclusion criteria: * do not meet inclusion criteria * history of schizophrenia, other neurocognitive illness (including severe tbi by intrust criteria)) or active alcohol and/or drug abuse determined by chart review, interview or audit-c score * inability to complete study tests within 18 months of study start * pregnancy
sleep health enhancement in older adults to address frailty

Conditions: Frailty

Summary: the objective of the proposed study is to tailor a sleep health enhancement intervention to older adults and assess preliminary efficacy on reducing frailty in older adults. this pilot study will be conducted in two stages. in the treatment development stage, we will recruit n=10 older individuals age ≥65 with poor sleep health (≤ 7 on the ru-sated self-report questionnaire) to assess acceptability and tailor the sleep health enhancement intervention for older adults. in the pilot study stage to assess preliminary efficacy of the tailored sleep health enhancement intervention, n=30 older adults with poor sleep health will be randomly assigned to a 4-week 1x/week, telehealth-delivered sleep health enhancement intervention or to a wait-list control condition. participants will wear wrist-worn actigraphy, complete sleep, frailty, and quality of life questionnaires at baseline and reassessments.


Eligibility criteria:
inclusion criteria: * ≥65 years old * ≤ 7 on the ru-sated self-report questionnaire * mmse ≥25 and ad8 \<3 exclusion criteria: * known untreated sleep disorder (such as sleep apnea or restless leg syndrome) * \>3 on the stop bang indicating increased risk of sleep apnea * evidence of restless legs syndrome on rls-diagnosis index * evidence of circadian rhythm sleep-wake disorder * evidence of parasomnia * regular use (\>2x/week) of prescription or over-the-counter medications to improve sleep * score of ≥15 on the patient health questionnaire (phq-9) indicating severe depression or endorse any suicidal ideation (answer 1, 2 or 3 on #9 of the phq-9) * score of ≥10 on the generalized anxiety disorder (gad-7) indicating moderate to severe anxiety * self-report of current or history (up to 2 years) of drug or alcohol abuse based on the dsm-v criteria * history of nervous system disorder such as stroke or parkinson's disease * severe mental illness such as schizophrenia or bipolar disorder * current or history (within 5 years) of shift work including hours of midnight-4am * is currently receiving a behavioral sleep health intervention

Keywords: sleep health older adults
platelet function and neurological events

Conditions: Stroke, Acute; Carotid Artery Diseases

Summary: several studies have shown an association between platelet function and stroke in patients undergoing carotid thromboendarterectomy (tea). the present study will assess the correlation between platelet function evaluated by the impedance aggregometry and neurological events in patients undergoing carotid tea.

carotid thrombendarterectomy (tea) is effective in preventing strokes which are a major cause of mortality and morbidity. nevertheless, almost 10% of patients undergoing tea develop a transient and/or permanent neurological injury. there is a growing body of evidence that platelet function is associated with perioperative neurological events in this setting, although the vast majority of patients undergoing carotid tea are already on antiplatelet agents. the aim of the present study will be to assess the correlation between the platelet function evaluated by the impedance aggregometry (multiplate ® analyzer, roche, basel, switzerland) and neurological events in patients undergoing carotid tea.

Eligibility criteria:
inclusion criteria: * age \> 18 years * carotid artery diseases undergoing carotid thrombendarterectomy * signed consent exclusion criteria: * atrial fibrillation * new oral anticoagulant * oral vitamin k inhibitors * platelet count \<80000 per microliter * ongoing ischemic stroke

Keywords: carotid thromboendarterectomy thromboembolic stroke platelet function aggregometry vascular surgery mortality neurological events
evaluation of the change in length of the leg in children after treatment of femur fractures.

Conditions: Fractures

Summary: femur fractures are a common injury in the pediatric population. despite their high incidence little do we know about the long term implications on the bones' length. our main goal is to clarify this obscure issue by assessing the femoral and tibial length as determined by the fractures, measuring techniques and treatment modalities


Eligibility criteria:
inclusion criteria: * males between the ages 0-16. * females between the ages 0-14. * signed informed consent exclusion criteria: * a refusal by the patient or his legal guardian to continue the follow-up with the * pediatric orthopedic clinic, or to have the ct scanograms. * patients with severe contractures in the lower extremities * patients with multiple lower extremity fractures * pregnancy
chemotherapy plus rituximab combination for adult lymphoblastic leukemia (b-all) and burkitt's non-hodgkin lymphoma

Conditions: Burkitt Lymphoma; B-ALL

Summary: the study was set up to assess the efficacy and tolerability of a chemotherapy-immunotherapy combination programme originally introduced by gmall (the german cooperative group for adult acute lymphoblastic leukemia)in 2002, to improve remission rate, overall and disease-free survival rates of adult patients with burkitt's leukemia and lymphoma. the therapy includes a maximum of six chemotherapy courses (two with high doses of methotrexate and cytarabine) plus anti-cd20 antibody (rituximab, up to 8 total doses), supplemented by local radiation therapy in the case of initial mediastinal or central nervous system (cns) involvement or a residual tumor after chemotherapy.

cycle a1: prednisone-cyclophosphamide pre-phase (5 days), rituximab on day 0, chemotherapy on days 1-5 (dexamethasone, iphosphamide, vincristine, high-dose methotrexate, triple intrathecal therapy). cycle b1: rituximab on day 0, chemotherapy on days 1-5 (dexamethasone, vincristine, cyclophosphamide, high-dose methotrexate, adriamycin, triple intrathecal therapy) cycle c1: rituximab on day 0, chemotherapy on days 1-5 (dexamethasone, vindesine, high-dose methotrexate, etoposide, high-dose cytarabine). cycle a2: like cycle a1, without pre-phase. cycle b2: like cycle b1. cycle c2: like cycle c1. cycle c2 is followed by two additional rituximab injections. notes: 1. patients with stage i-ii disease without mediastinal tumor or extranodal involvement receive only the first 4 cycles (a1 to a2). 2. patients aged \>55 years do not receive cycles c (sequence: a1, b1, a2, b2, a3, b3 or a1, b1, a2, b2 if limited stage, with reduced-dose methotrexate).

Eligibility criteria:
inclusion criteria: * burkitt's leukemia or lymphoma (new diagnosis) * written informed consent * age \> 15 years exclusion criteria: * pre-treated burkitt's leukemia or lymphoma * psychiatric disorders * active second malignancy * pregnancy * absence of patient's written informed consent * participation in other studies that interfere with the study therapy

Keywords: burkitt lymphoma b-all adult patients
study of sunitinib in combination with cisplatin/capecitabine or oxaliplatin/capecitabine in patients with advanced gastric cancer

Conditions: Stomach Neoplasms

Summary: the purpose of the study is to determine the safe and tolerable doses of sunitinib given together with either cisplatin and capecitabine or oxaliplatin and capecitabine in patients who have advanced gastric cancer who have not received prior chemotherapy for their advanced cancer


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of stomach cancer * advanced stomach cancer of stage iv * adequate blood chemistry, blood counts and kidney function * willing to participate to study requirements and sign an informed consent document exclusion criteria: * prior chemotherapy for the stomach cancer in its advanced stage * excessive toxicities related to prior therapies * pregnant or breastfeeding patients
the application of performance improvement principles to the patient throughput process in an adult outpatient pain treatment clinic

Conditions: Chronic Pain

Summary: this study is undertaken to assess and improve the existing patient flow, or so-called throughput process, in an adult outpatient pain treatment clinic.


Eligibility criteria:
inclusion criteria: * 19-100 years of age. * patient presenting to the uab highlands pain treatment clinic for initial evaluation and treatment or subsequent follow-up evaluation and treatment. exclusion criteria: * \ 100 years of age * a current prisoner

Keywords: chronic pain
a questionnaire survey for biliary tract cancers

Conditions: Biliary Tract Cancer

Summary: the purpose of this study is: * to evaluate risk factors for cancers of the biliary tract by registering new patients and their counterparts in a multi-center program * development of programs by creating a multi-center biliary tract cancer registration system


Eligibility criteria:
inclusion criteria: * study population : * newly diagnosis of biliary tract cancers - pathological or radiological or other clinical diagnosis of biliary tract cancers * informed consent * control : * with no previous cancer diagnosis * informed consent exclusion criteria: * previous diagnosis of bile duct cancer with resection operation, endoscopic resection, chemotherapy or radiation therapy * prior diagnosis of other cancer in 5 years or ongoing cancer treatment * patients' refusal
the importance of periostin in periodontal health and disease

Conditions: Periodontal Disease; Non-diseased Patients

Summary: the goal of this study is to determine the clinical importance of periostin in oral health and disease. the long-term goal will be to develop practical applications for the diagnosis, treatment, prevention and cure of human periodontal diseases.

it is hypothesized that periostin levels are decreased during periodontal diseases, thereby, elevating the hosts' susceptibility to periodontal breakdown. the specific aims are the following; to determine if periostin is a biomarker of periodontal disease, and to evaluate periostin in periodontal tissue healing and homeostasis by harvesting healthy or diseased tissue from 22 patients requiring periodontal surgery.

Eligibility criteria:
inclusion criteria: inclusion criteria for diseased subjects: * diagnosis of generalized chronic or aggressive periodontitis * at least four periodontal sites with probing depth (pd) ≥6 mm, evidence of clinical attachment loss (cal), and bleeding on probing (bop). inclusion criteria for healthy individuals will include pd \<4 mm, no evidence of attachment loss, and \<10% of sites with bop * need an open flap procedure inclusion criteria for non-diseased subjects: * subjects requiring a gingivectomy or crown lengthening procedure exclusion criteria: * history of alcoholism or drug abuse * medical conditions that may affect the outcome such as autoimmune diseases, diabetes, immunocompromised subjects, neurologic or psychiatric disorders, systemic infections, etc. * chronic medications known to affect the periodontal status (calcium antagonists, anticonvulsives, immunosuppressives, anti-inflammatory medications, depo-provera contraceptive injection users, new oral contraceptives users within 3 months of baseline or subjects that are planning on, starting oral contraceptives during the study. * antibiotic therapy within 3 months of the baseline visit, and/or antibiotic therapy needed for infective endocarditis prophylaxis. * current use or quit smoking less than one year ago with a pack-year history of more than or equal to 10. * untreated cavities

Keywords: dental periodontal surgery gums